Unlock instant, AI-driven research and patent intelligence for your innovation.
Applications of bigelovii A in preparing drugs used for preventing and treating inflammatory diseases
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of saponin A and saponin A, applied in the application field of a pharmaceutical composition, can solve problems such as no reports on the action of saponin A in saponin
Active Publication Date: 2015-10-28
INST OF BOTANY JIANGSU PROVINCE & CHINESE ACADEMY OF SCI
View PDF1 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0019] Example 1 Cytotoxicity Test of Salicornia saponin A
[0021] RAW264.7 cells (2×10 5 cells / well) were inserted into 96-well culture plates and cultured overnight, and different concentrations of salicordin A (1, 2, 4, 6, 8, 10 μg / ml, DMSO was used as a blank control) were added for 24 hours, and then Add MTT to a final concentration of 0.5 mg / ml for 4 hours, add DMSO at 100 μl / well, shake for 15 minutes, and read the absorbance at a wavelength of 570 nm.
[0022] OD 570 Can reflect the growth of cells, according to OD 570 Calculate the cell viability to judge whether salicordin A has cytotoxicity.
[0023] The results of the MTT method showed that (see figure 2 ): Salicordin A has basically no cytotoxicity to RAW264.7 cells at a concentration of 1-10 μg / ml.
Embodiment 2
[0024] Example 2 Salicordin A inhibits prostaglandin E 2 (PGE 2 )effect
[0025] Mouse macrophages RAW264.7 in the logarithmic growth phase were spread on 24-well plates, adhered to the wall overnight, added saponin A or positive control indomethacin, and 100 ng / ml LPS was added for 24 hours after 2 hours. Collect the cellculture fluid, 1000g, 15min, use the competitive ELISA method to detect the prostaglandin E in the supernatant 2 . see results image 3 .
[0026] Compared with the LPS-induced inflammation model group, after administration of salicordin A, LPS induced prostaglandin E secreted by mouse macrophage RAW264.7 2 Significantly reduced, and showed a good dose-dependent.
Embodiment 3
[0027] Example 3 Salicordin A inhibits the action of inflammatory factor nitric oxide (NO)
[0028] RAW264.7 cells (1×10 6 Cells / mL) were inserted into 96-well culture plates and cultured overnight, then different concentrations of salicordin A (0.1, 1, 10 μg / ml, DMSO was used as blank control), and then 100 ng / ml LPS was added to stimulate After 24 hours, the cell culture supernatant was collected, and the content of nitric oxide (NO) was detected by the Griess method.
[0029] Experimental results (see Figure 4 ) showed that: Salicornia saponin A can inhibit bacterial lipopolysaccharide-induced nitric oxide production in RAW264.7 cells in a dose-dependent manner.
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention belongs to the field of natural drug, and relates to applications of specific monomer bigelovii A in Salicornia bigelovii Torr. in preparing drug compositions, and especially in preparing drug compositions used for preventing and treating inflammatory diseases. It is shown by in vitroinflammation model experiments that bigelovii A is capable of inhibiting generation of inflammatory induced prostaglandin E2 and release of nitric oxide; it is fond by in vivo experiments on animals that bigelovii A is capable of inhibiting phorbol ester induced mouse ear swelling; and it is confirmed by experiments that bigelovii A possesses obvious anti-inflammatory action on inflammatory diseases, and can be used for preparing drugs used for preventing and treating inflammatory diseases, wherein the inflammatory diseases include acute lung injury, rheumatic arthritis, inflammatory bowel disease, neurodegenerative disease, and septic shock.
Description
technical field [0001] The invention relates to the field of natural medicines, in particular to the application of a specific monomersalicorniasaponin A (Bigelovii A) in the preparation of pharmaceutical compositions, especially in the preparation of pharmaceutical compositions for preventing and treating inflammation-related diseases. application. Background technique [0002] Inflammatory response is one of the important components of the body's immune system, which is precisely regulated by the body through various channels. However, when the inflammatory response is uncontrollable, it will lead to a variety of diseases in the body, such as acute lung injury (acute lung injury), rheumatoid arthritis (rtheumatoid arthritis), inflammatory bowel disease (Inflammatory bowel disease, IBD), neurodegenerative Disease (neurodegenerative disorder) and septic shock (septic shock syndrome), etc., long-term inflammatory response stimulation can also induce body cancer (1, Zhu et ...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More